Technology
Fab’entech’s platform is used for the development and manufacturing of immunotherapies composed of highly purified F(ab’)2 fragments of horse specific polyclonal immunoglobulins.
This technology has been developed by Sanofi Pasteur, then in-licensed by Fab'entech. Such platform having been fully-validated with the development of Fabenflu®, Fab’entech can develop and manufacture, in a short period of time and for limited investments, new immunotherapies from high quality & security standards.
MANUFACTURING
Fab'entech's manufacturing activities are currently performed in the R&D laboratory located in its principal office in Lyon.
However, in order to align its industrial capacity with its R&D pipeline, Fab'entech is also building an industrial manufacturing site based on a modular system, which is located only 15 minutes away from its Lyon office, and with which it will be able to produce clinical batches at short-term and commercial batches at mid-term.
PUBLICATIONS